Can you provide a timeline for apotex's ruxolitinib approval and launch in the us?

What’s the US approval-and-launch timeline for Apotex’s ruxolitinib?

The provided information does not include any details about Apotex’s ruxolitinib US regulatory approval date, the FDA approval reference (e.g., NDA/BLA submission), or the US launch date. Because of that, I can’t produce an accurate timeline for Apotex’s approval and launch based on the materials available to me.

If you meant “Apotex ruxolitinib” broadly (not specifically which product)?

Ruxolitinib has at least one major branded product in the US (Jakafi), and multiple generic/biosimilar alternatives could be involved depending on the specific sponsor, strength, formulation, and legal pathway. A timeline would need the exact Apotex product name and application type (and ideally the FDA approval date).

What I need from you to build the timeline

Share any of the following, and I can turn it into a clean approval-and-launch timeline:
- The exact product name/strength (and whether it’s oral tablets or another formulation)
- The FDA application identifier (NDA/BLA number) or an FDA approval announcement link
- The company entity name you mean by “Apotex” (e.g., Apotex Inc. vs another Apotex-linked labeler in the US)
- Whether you’re asking about “first approval” or “launch date after approval” for a specific strength/package

Sources

No sources were provided with the question, so there’s nothing I can cite for an Apotex ruxolitinib US timeline.